Global Trial in APG2575 for Patients With CLL/SLL

NCT06104566 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

CLL/SLL

Interventions

DRUG: lisaftoclax +BTK inhibitor
DRUG: BTK inhibitor

Sponsor

Ascentage Pharma Group Inc.